Successful Rechallenge of Trastuzumab Deruxtecan After Drug-Induced Interstitial Lung Disease in a NSCLC With HER2 Mutation: A Case Report

Successful Rechallenge of Trastuzumab Deruxtecan After Drug-Induced Interstitial Lung Disease in a NSCLC With HER2 Mutation: A Case Report

Trastuzumab deruxtecan, an antibody-drug conjugate targetingHER2-expressing tumor cells, was found to have promising results in treatment-refractory, metastatic NSCLC harboring HER2 mutations. Nevertheless, drug-induced interstitial lung disease (ILD)/pneumonitis is a concern that limits treatment r...

Täydet tiedot

Bibliografiset tiedot
Päätekijät: Sangho Nam, MD, Sun Min Lim, MD, PhD, Byoung Chul Cho, MD, PhD, Jii Bum Lee, MD
Aineistotyyppi: Artikkeli
Kieli:English
Julkaistu: Elsevier 2024-02-01
Sarja:JTO Clinical and Research Reports
Aiheet:
Trastuzumab deruxtecan
Interstitial lung disease
ERBB2 Y772-A775
Non–small cell lung cancer
Case report
Linkit:http://www.sciencedirect.com/science/article/pii/S2666364323001716

Internet

http://www.sciencedirect.com/science/article/pii/S2666364323001716

Samankaltaisia teoksia